

New Hampshire Medicaid Fee-for-Service Program

Carisoprodol and Combination Medication Criteria

Approval Date: June 5, 2025

Medications

| Brand Names | Generic Names | Dosage |
|--|------------------------------|---|
| Soma® | carisoprodol | <ul style="list-style-type: none"> 250 mg, 350 mg 3 times per day at and at bedtime |
| Soma compound® (for reference only) | carisoprodol/ASA | <ul style="list-style-type: none"> carisoprodol 200 mg, plus aspirin 325 mg 1 or 2 tablets, 4 times a day Max dose: 2 tablets, 4 times per day |
| Soma Compound with Codeine® (for reference only) | carisoprodol/ASA/ codeine | <ul style="list-style-type: none"> carisoprodol 200 mg, aspirin 325 mg, codeine phosphate 16 mg/tablet 1 or 2 tablets, 4 times a day Max dose: 2 tablets, 4 times per day |

Critical Information

Medicaid covers several other muscle relaxants and prefers not to have this authorized because of abuse potential. A change in therapy should be offered.

Criteria for Approval

- FDA-approved indication: **Musculoskeletal pain**
 - carisoprodol:** relief of discomfort or pain related to acute musculoskeletal conditions in adults
 - carisoprodol/ASA:** acute, painful musculoskeletal conditions in adults
 - carisoprodol/ASA/codeine:** acute, painful musculoskeletal conditions in adults. Reserve use for patients in whom alternative options have not been or are not expected to be tolerated or adequate. Even at usual doses there are risks of opioid addiction, abuse, and misuse; **AND**
- Patient has a defined failure or contraindication or intolerance to a trial of one preferred analgesic and two preferred skeletal muscle relaxants prior to use of carisoprodol-containing products; **AND**
- Prescribed utilization is for short-term (up to three consecutive weeks at a time) therapy.

Approval Period: Three weeks

Quantity Limit:

- Carisoprodol:** Maximum four units per day
- Carisoprodol combinations:** Maximum eight units per day

Proprietary & Confidential

© 2019–2025 Prime Therapeutics State Government Solutions LLC, a Prime Therapeutics LLC company

Criteria for Denial

1. Failure to meet criteria for approval; **OR**
2. Active substance use disorder; **OR**
3. History of gastrointestinal (GI) bleed for aspirin-containing products.

References

Available upon request.

Revision History

| Reviewed by | Reason for Review | Date Approved |
|-----------------------|-------------------|---------------|
| DUR Board | New | 03/12/2019 |
| Commissioner Designee | New | 04/05/2019 |
| DUR Board | Revision | 06/30/2020 |
| Commissioner Designee | Approval | 08/07/2020 |
| DUR Board | Revision | 12/15/2020 |
| Commissioner Designee | Approval | 02/24/2021 |
| DUR Board | Revision | 06/02/2022 |
| Commissioner Designee | Approval | 07/12/2022 |
| DUR Board | Revision | 12/08/2023 |
| Commissioner Designee | Approval | 01/22/2024 |
| DUR Board | Revision | 04/08/2025 |
| Commissioner Designee | Approval | 06/05/2025 |